RT @kamleshkhunti: Secondary analysis of SPRINT trial Benefits seen at 3.3 years follow-up not maintained at 8.8 yrs https://t.co/P2lKofE…
RT @kamleshkhunti: Secondary analysis of SPRINT trial Benefits seen at 3.3 years follow-up not maintained at 8.8 yrs https://t.co/P2lKofE…
RT @kamleshkhunti: Secondary analysis of SPRINT trial Benefits seen at 3.3 years follow-up not maintained at 8.8 yrs https://t.co/P2lKofE…
Study included 102 clinic sites in the US and Puerto Rico#Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control https://t.co/PXMsAIspSh via @JAMACardio part of @JAMANetwork
RT @kamleshkhunti: Secondary analysis of SPRINT trial Benefits seen at 3.3 years follow-up not maintained at 8.8 yrs https://t.co/P2lKofE…
RT @spjuraschek: Great paper using SPRINT follow-up data to show the need to maintain BP at goal long-term to prevent cardiovascular diseas…
RT @alta_schutte: 10 years after randomisation of SPRINT "mortality benefits associated with intensive treatment quickly attenuated" 🔑 -…
RT @VCUDPOSChair: This provides further evidence that Systolic BP Time in Target Range could be a potential therapeutic target and quality…
RT @spjuraschek: Great paper using SPRINT follow-up data to show the need to maintain BP at goal long-term to prevent cardiovascular diseas…
Amen. Cc @DaichiShimbo @Aging_MD @MichaelJBlaha @mdmiedema @khurramn1 @ErinMichos @MichaelGNanna
RT @kamleshkhunti: Secondary analysis of SPRINT trial Benefits seen at 3.3 years follow-up not maintained at 8.8 yrs https://t.co/P2lKofE…
RT @VCUDPOSChair: This provides further evidence that Systolic BP Time in Target Range could be a potential therapeutic target and quality…
RT @VCUDPOSChair: This provides further evidence that Systolic BP Time in Target Range could be a potential therapeutic target and quality…
This provides further evidence that Systolic BP Time in Target Range could be a potential therapeutic target and quality metric. This also reinforces the importance of consistent, long-term BP control as recently demonstrated in this @JAMACardio paper: h
RT @kamleshkhunti: Secondary analysis of SPRINT trial Benefits seen at 3.3 years follow-up not maintained at 8.8 yrs https://t.co/P2lKofE…
RT @kamleshkhunti: Secondary analysis of SPRINT trial Benefits seen at 3.3 years follow-up not maintained at 8.8 yrs https://t.co/P2lKofE…
RT @alta_schutte: 10 years after randomisation of SPRINT "mortality benefits associated with intensive treatment quickly attenuated" 🔑 -…
RT @kamleshkhunti: Secondary analysis of SPRINT trial Benefits seen at 3.3 years follow-up not maintained at 8.8 yrs https://t.co/P2lKofE…
RT @kamleshkhunti: Secondary analysis of SPRINT trial Benefits seen at 3.3 years follow-up not maintained at 8.8 yrs https://t.co/P2lKofE…
RT @kamleshkhunti: Secondary analysis of SPRINT trial Benefits seen at 3.3 years follow-up not maintained at 8.8 yrs https://t.co/P2lKofE…
RT @kamleshkhunti: Secondary analysis of SPRINT trial Benefits seen at 3.3 years follow-up not maintained at 8.8 yrs https://t.co/P2lKofE…
Secondary analysis of SPRINT trial Benefits seen at 3.3 years follow-up not maintained at 8.8 yrs https://t.co/P2lKofEwrO https://t.co/xo9s3DQBu0
RT @alta_schutte: 10 years after randomisation of SPRINT "mortality benefits associated with intensive treatment quickly attenuated" 🔑 -…
Great paper using SPRINT follow-up data to show the need to maintain BP at goal long-term to prevent cardiovascular disease. @NMPajewski @JAMACardio https://t.co/PX5cdwXnWK
RT @alta_schutte: 10 years after randomisation of SPRINT "mortality benefits associated with intensive treatment quickly attenuated" 🔑 -…
RT @alta_schutte: 10 years after randomisation of SPRINT "mortality benefits associated with intensive treatment quickly attenuated" 🔑 -…
RT @alta_schutte: 10 years after randomisation of SPRINT "mortality benefits associated with intensive treatment quickly attenuated" 🔑 -…
RT @SBurtey: Un peu de SPRINT, ça faisait longtemps, quand tu sors de l'essai clinique, la tension artérielle est moins bien contrôlée et l…
RT @alta_schutte: 10 years after randomisation of SPRINT "mortality benefits associated with intensive treatment quickly attenuated" 🔑 -…
Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control: A Secondary Analysis of a Randomized Clinical Trial | Cardiology | JAMA Cardiology | JAMA Network✅✅✅ https://t.co/3ZyQBflgBQ
RT @alta_schutte: 10 years after randomisation of SPRINT "mortality benefits associated with intensive treatment quickly attenuated" 🔑 -…
10 years after randomisation of SPRINT "mortality benefits associated with intensive treatment quickly attenuated" 🔑 - not to take foot of the pedal in #bloodpressure management! https://t.co/bQhgplixdD via @JAMACardio part of @JAMANetwork https://t.co/
SPRINT trial At median 8.8 years follow up there was no difference in CVD and all cause mortality between standard and intensive treatment of hypertension.
Intensive blood pressure management is better https://t.co/YYG2XEEZBZ https://t.co/iYnoawcVgR
Another "real life" HTN treatment results: Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control https://t.co/XlRBr8MDaV via @JAMACardio part of @JAMANetwork https://t.co/C3OCH4sozO
RT @rincondesisifo: (JAMA) Mortalidad CV y por cualquier causa a largo plazo con un tratamiento antihipertensivo intensivo https://t.co/DqV…
Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control https://t.co/rUhz3Cepzy via @JAMACardio part of @JAMANetwork
RT @SBurtey: Un peu de SPRINT, ça faisait longtemps, quand tu sors de l'essai clinique, la tension artérielle est moins bien contrôlée et l…
RT @SBurtey: Un peu de SPRINT, ça faisait longtemps, quand tu sors de l'essai clinique, la tension artérielle est moins bien contrôlée et l…
RT @VPrasadMDMPH: Wow! Sprint was always terrible. You can't forcibly down titrate BP meds if someone asymptomatic 👇👇that's not 'standard'…
RT @VPrasadMDMPH: Wow! Sprint was always terrible. You can't forcibly down titrate BP meds if someone asymptomatic 👇👇that's not 'standard'…
RT @VPrasadMDMPH: Wow! Sprint was always terrible. You can't forcibly down titrate BP meds if someone asymptomatic 👇👇that's not 'standard'…
RT @VPrasadMDMPH: Wow! Sprint was always terrible. You can't forcibly down titrate BP meds if someone asymptomatic 👇👇that's not 'standard'…
RT @VPrasadMDMPH: Wow! Sprint was always terrible. You can't forcibly down titrate BP meds if someone asymptomatic 👇👇that's not 'standard'…
RT @VPrasadMDMPH: Wow! Sprint was always terrible. You can't forcibly down titrate BP meds if someone asymptomatic 👇👇that's not 'standard'…
RT @VPrasadMDMPH: Wow! Sprint was always terrible. You can't forcibly down titrate BP meds if someone asymptomatic 👇👇that's not 'standard'…
Wow! Sprint was always terrible. You can't forcibly down titrate BP meds if someone asymptomatic 👇👇that's not 'standard' Mark explained why the trial was worthless on @Plenary_Session; new results esp concerning https://t.co/10RjXGKqHC
Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control https://t.co/XouGVrbteX vía @JAMACardio part of @JAMANetwork
Trials and tribulations…reality is hard. Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control: A Secondary Analysis @JAMA_current @JAMACardio #nephtwitter #cardiotwitter #hypertension https://t.co/mZ7ijL5cE7
RT @rincondesisifo: (JAMA) Mortalidad CV y por cualquier causa a largo plazo con un tratamiento antihipertensivo intensivo https://t.co/DqV…
RT @DrDerekConnolly: Sustaining BP control to the Systolic Blood Pressure Intervention Trial target of 💥less than 120 mm Hg💥will be critica…
RT @DrDerekConnolly: Sustaining BP control to the Systolic Blood Pressure Intervention Trial target of 💥less than 120 mm Hg💥will be critica…
RT @DrDerekConnolly: Sustaining BP control to the Systolic Blood Pressure Intervention Trial target of 💥less than 120 mm Hg💥will be critica…
RT @JAMACardio: In a secondary analysis of SPRINT, the mortality benefits of intensive BP control attenuated after the trial, while outpati…
RT @byronjaeger1: New article in JAMA Cardio! We investigated the long-term effect of reducing systolic BP to <120 mm Hg for ~3 years on CV…
RT @JAMACardio: In a secondary analysis of SPRINT, the mortality benefits of intensive BP control attenuated after the trial, while outpati…
RT @gunnar_heine: No legacy effect of intensive blood pressure control in SPRINT https://t.co/FkmjYnfO7E via @JAMACardio part of @JAMANetwo…
RT @rincondesisifo: (JAMA) Mortalidad CV y por cualquier causa a largo plazo con un tratamiento antihipertensivo intensivo https://t.co/DqV…
RT @rincondesisifo: (JAMA) Mortalidad CV y por cualquier causa a largo plazo con un tratamiento antihipertensivo intensivo https://t.co/DqV…
RT @rincondesisifo: (JAMA) Mortalidad CV y por cualquier causa a largo plazo con un tratamiento antihipertensivo intensivo https://t.co/DqV…
RT @gunnar_heine: No legacy effect of intensive blood pressure control in SPRINT https://t.co/FkmjYnfO7E via @JAMACardio part of @JAMANetwo…
RT @rincondesisifo: (JAMA) Mortalidad CV y por cualquier causa a largo plazo con un tratamiento antihipertensivo intensivo https://t.co/DqV…
RT @gunnar_heine: No legacy effect of intensive blood pressure control in SPRINT https://t.co/FkmjYnfO7E via @JAMACardio part of @JAMANetwo…
RT @gcfmd: Did SPRINT patients in the intensive arm maintain SBP levels after the trial showed the benefits of dosing so? Nope Longer-Ter…
RT @gunnar_heine: No legacy effect of intensive blood pressure control in SPRINT https://t.co/FkmjYnfO7E via @JAMACardio part of @JAMANetwo…
👇
(JAMA) Mortalidad CV y por cualquier causa a largo plazo con un tratamiento antihipertensivo intensivo https://t.co/DqVqtYYl72 Análisis 2º del #SPRINT Editorial https://t.co/GI8k17dUjI OJO!! https://t.co/c8auybukfk
RT @gunnar_heine: No legacy effect of intensive blood pressure control in SPRINT https://t.co/FkmjYnfO7E via @JAMACardio part of @JAMANetwo…
RT @gunnar_heine: No legacy effect of intensive blood pressure control in SPRINT https://t.co/FkmjYnfO7E via @JAMACardio part of @JAMANetwo…
No addl benefits on CVD & all-cause mortality on strict blood pressure control (SBP <120). https://t.co/uMPr6bJfDf via @JAMACardio part of @JAMANetwork
Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control: A Secondary Analysis of a Randomized Clinical Trial | Cardiology | JAMA Cardiology | JAMA Network https://t.co/VkGbqRXGc5
RT @gunnar_heine: No legacy effect of intensive blood pressure control in SPRINT https://t.co/FkmjYnfO7E via @JAMACardio part of @JAMANetwo…
RT @gunnar_heine: No legacy effect of intensive blood pressure control in SPRINT https://t.co/FkmjYnfO7E via @JAMACardio part of @JAMANetwo…
RT @gunnar_heine: No legacy effect of intensive blood pressure control in SPRINT https://t.co/FkmjYnfO7E via @JAMACardio part of @JAMANetwo…
RT @JAMACardio: In a secondary analysis of SPRINT, the mortality benefits of intensive BP control attenuated after the trial, while outpati…
RT @gunnar_heine: No legacy effect of intensive blood pressure control in SPRINT https://t.co/FkmjYnfO7E via @JAMACardio part of @JAMANetwo…
RT @JAMACardio: In a secondary analysis of SPRINT, the mortality benefits of intensive BP control attenuated after the trial, while outpati…
RT @gunnar_heine: No legacy effect of intensive blood pressure control in SPRINT https://t.co/FkmjYnfO7E via @JAMACardio part of @JAMANetwo…
No legacy effect of intensive blood pressure control in SPRINT https://t.co/FkmjYnfO7E via @JAMACardio part of @JAMANetwork @dgfn_ev @hswapnil @MarcusSaemann @floriancustodis @com_SFNDT @dguerrot
RT @JAMACardio: In a secondary analysis of SPRINT, the mortality benefits of intensive BP control attenuated after the trial, while outpati…
RT @JAMACardio: In a secondary analysis of SPRINT, the mortality benefits of intensive BP control attenuated after the trial, while outpati…
In a secondary analysis of SPRINT, the mortality benefits of intensive BP control attenuated after the trial, while outpatient systolic BP increased by an average of 7 mm Hg for participants in the intensive treatment group. https://t.co/GALdXP40Oe #Resear
No legacy effect for BP-lowering therapy on a secondary analysis of the SPRINT trial. Sustained intensive BP reduction in the real-world is the challenge. Link: https://t.co/gGYdixgzsf https://t.co/OUSk9QXAxT
RT @gcfmd: Did SPRINT patients in the intensive arm maintain SBP levels after the trial showed the benefits of dosing so? Nope Longer-Ter…
RT @gcfmd: Did SPRINT patients in the intensive arm maintain SBP levels after the trial showed the benefits of dosing so? Nope Longer-Ter…
RT @gcfmd: Did SPRINT patients in the intensive arm maintain SBP levels after the trial showed the benefits of dosing so? Nope Longer-Ter…
RT @JAMACardio: In a secondary analysis of SPRINT, the mortality benefits of intensive BP control attenuated after the trial, while outpati…
RT @gcfmd: Did SPRINT patients in the intensive arm maintain SBP levels after the trial showed the benefits of dosing so? Nope Longer-Ter…
Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control: A Secondary Analysis of a Randomized Clinical Trial | Cardiology | JAMA Cardiology | JAMA Network https://t.co/05bF5oTHc5
RT @gcfmd: Did SPRINT patients in the intensive arm maintain SBP levels after the trial showed the benefits of dosing so? Nope Longer-Ter…
RT @gcfmd: Did SPRINT patients in the intensive arm maintain SBP levels after the trial showed the benefits of dosing so? Nope Longer-Ter…
RT @gcfmd: Did SPRINT patients in the intensive arm maintain SBP levels after the trial showed the benefits of dosing so? Nope Longer-Ter…
RT @gcfmd: Did SPRINT patients in the intensive arm maintain SBP levels after the trial showed the benefits of dosing so? Nope Longer-Ter…
RT @NMPajewski: Some new work from SPRINT, of the not unexpected, but disappointing variety. Not going to shock anyone, but for blood press…
Sobering results. #hypertension
RT @gcfmd: Did SPRINT patients in the intensive arm maintain SBP levels after the trial showed the benefits of dosing so? Nope Longer-Ter…
RT @NMPajewski: Some new work from SPRINT, of the not unexpected, but disappointing variety. Not going to shock anyone, but for blood press…
RT @byronjaeger1: New article in JAMA Cardio! We investigated the long-term effect of reducing systolic BP to <120 mm Hg for ~3 years on CV…
RT @byronjaeger1: New article in JAMA Cardio! We investigated the long-term effect of reducing systolic BP to <120 mm Hg for ~3 years on CV…
2944例解析では、試験開始5年後の群間血圧差は5.9mmHg、10年後は差なし。 https://t.co/3IWD0FONvR